Cementos Pacasmayo S.A.A. (NYSE:CPAC – Get Free Report) shares reached a new 52-week high on Monday . The stock traded as high as $6.65 and last traded at $6.65, with a volume of 7005 shares. The stock had previously closed at $6.53.
Wall Street Analyst Weigh In
Separately, JPMorgan Chase & Co. lowered shares of Cementos Pacasmayo S.A.A. from a “neutral” rating to an “underweight” rating and set a $6.00 target price for the company. in a research report on Wednesday, August 21st.
Check Out Our Latest Research Report on CPAC
Cementos Pacasmayo S.A.A. Price Performance
Cementos Pacasmayo S.A.A. (NYSE:CPAC – Get Free Report) last posted its earnings results on Tuesday, October 29th. The construction company reported $0.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.15 by $0.01. The company had revenue of $137.76 million during the quarter, compared to analyst estimates of $140.30 million. Cementos Pacasmayo S.A.A. had a return on equity of 17.48% and a net margin of 9.41%. On average, sell-side analysts anticipate that Cementos Pacasmayo S.A.A. will post 0.49 EPS for the current year.
About Cementos Pacasmayo S.A.A.
Cementos Pacasmayo SAA., a cement company, produces, distributes, and sells cement and cement-related materials in Peru. It operates through three segments: Cement, Concrete, Mortar and Precast; Quicklime; and Sales of Construction Supplies. The company’s cement and concrete products are used in residential and commercial construction, and civil engineering; ready-mix concrete used in construction sites; concrete precast, such as paving units or paver stones for pedestrian walkways, as well as other bricks for partition walls and concrete precast for structural and non-structural uses; and cement-based products.
Recommended Stories
- Five stocks we like better than Cementos Pacasmayo S.A.A.
- Consumer Staples Stocks, Explained
- Intel: Is Now the Time to Be Brave?
- Why Are These Companies Considered Blue Chips?
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- What is a Special Dividend?
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for Cementos Pacasmayo S.A.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cementos Pacasmayo S.A.A. and related companies with MarketBeat.com's FREE daily email newsletter.